Form 4: Skorpios Trust Sells 2 Million Shares of Stoke Therapeutics
SEC Form 4 Filing
Skorpios Trust, a significant shareholder of Stoke Therapeutics, sold 2 million shares of common stock at $11.50 per share.
Summary
- Skorpios Trust sold 2,000,000 shares of Stoke Therapeutics common stock on December 23, 2024, at a price of $11.50 per share.
- Following the transaction, Skorpios Trust indirectly beneficially owns 6,906,181 shares.
- The shares are indirectly held through Blue Horizon Enterprise Ltd. and Ezbon International Limited, both of which are wholly owned by Skorpios Trust.
- Montrago Trustees Limited acts as the corporate trustee of Skorpios Trust.
- Blue Horizon directly owns 2,967,621 shares, and Ezbon directly owns 3,938,560 shares of Stoke Therapeutics common stock.
Sentiment
Score: 4
Explanation: The sale of a significant number of shares by a major shareholder is generally viewed negatively, but the transaction itself is not unusual.
Negatives
- The sale of 2 million shares by a major shareholder could be perceived negatively by the market.
Risks
- The sale by Skorpios Trust could indicate a change in their investment outlook for Stoke Therapeutics.
- Further sales by Skorpios Trust could put downward pressure on the stock price.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders and major shareholders, providing transparency to the market.
Comparison to Industry Standards
- Form 4 filings are a common occurrence for publicly traded companies, and this transaction is within the normal range of insider activity.
- The sale of 2 million shares is a significant transaction, but not unusual for a major shareholder.
Stakeholder Impact
- The share sale could negatively impact shareholder confidence and potentially lead to a decrease in the stock price.
- The sale may not have a direct impact on employees, customers, or suppliers.
Key Dates
| Date | Description |
|---|---|
| 12/23/2024 | Date of the share sale transaction. |
| 12/27/2024 | Date of the filing of the Form 4. |
Keywords
Stoke Therapeutics, Skorpios Trust, share sale, insider trading, stock transaction, beneficial ownership, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.